Abstract
Cell therapy efforts for treating HIV+ patients are challenged by limited availability of donors with naturally occurring CCR5 mutations conferring resistance. Xu etal. (2019) report a CRISPR-based method for disrupting CCR5 in hematopoietic stem cells prior to transplant, providing a proof of concept for expanding the pool of potential donors.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
